Celcuity (FRA:7VR) 3-Year RORE % : 9.05% (As of Mar. 2026)


FRA:7VR Celcuity Inc FRA:7VR
11 GF Score
Price €91.50
! 2 Warning Signs
View Full Analysis

What is Celcuity 3-Year RORE %?

Celcuity FRA:7VR +1.10% 11 3-Year RORE % is 9.05 as of Mar. 2026. GuruFocus rates FRA:7VR with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 1,289 Biotechnology companies, Celcuity ranks better than 75.02% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Celcuity's 3-Year RORE % for the quarter that ended in Mar. 2026 was 9.05%.

The industry rank for Celcuity's 3-Year RORE % or its related term are showing as below:

FRA:7VR's 3-Year RORE % is ranked better than
75.02% of 1289 companies
in the Biotechnology industry
Industry Median: -11.53 vs FRA:7VR: 9.05

Celcuity  (FRA:7VR) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Celcuity 3-Year RORE % Related Terms


Celcuity 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Celcuity's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celcuity 3-Year RORE % Chart

Celcuity Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 37.21 33.29 8.85 1.10 9.77

Celcuity Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.24 7.41 9.01 9.77 9.05

FRA:7VR vs ERAS, TNGX, DNTH: 3-Year RORE % Comparison

For the Biotechnology subindustry, Celcuity's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Celcuity 3-Year RORE % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celcuity's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Celcuity's 3-Year RORE % falls into.


FRA:7VR
11GF Score
Celcuity Inc FRA:7VR
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Celcuity 3-Year RORE % Calculation

Celcuity's 3-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -3.353--2.563 )/( -8.73-0 )
=-0.79/-8.73
=9.05 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of 9.05 mean?
Celcuity (FRA:7VR) has a 3-Year RORE % of 9.05 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Celcuity and its competitors. According to the industry distribution chart, Celcuity ranks #322 out of 1289 companies in the Biotechnology industry, placing it in the top 25%.
Is Celcuity's 3-Year RORE % too high?
Celcuity's current 3-Year RORE % is 9.05. Based on the distribution chart, Celcuity ranks #322 out of 1289 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Celcuity has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Celcuity's 3-Year RORE % compare to ERAS and TNGX?
According to the Biotechnology industry distribution chart, Celcuity ranks #322 out of 1289 companies for 3-Year RORE %. This places Celcuity in the top 25% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Celcuity and its competitors. Celcuity's current 3-Year RORE % is 9.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celcuity stock overvalued right now?
Celcuity (FRA:7VR) has a current 3-Year RORE % of 9.05. The current 3-Year RORE % is 9.05. Celcuity's overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Celcuity (FRA:7VR), the current 3-Year RORE % is 9.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Celcuity Business Description

Other Exchanges CELC:USA
Address 16305 36th Avenue North, Suite 100, Minneapolis, MN, USA, 55446
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
11GF Score

Get the complete analysis for FRA:7VR

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€91.50
Price